Study Details
Post-Marketing Study to evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination with GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes Mellitus (T2DM)
Clinicaltrials.gov ID
Astellas Study ID
1941-CL-0132
EudraCT ID
N/A
Condition
Adult Onset Diabetes
Phase
Phase 4
Age
20 years - N/A
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Oct 2014 - Jul 2016
Masking
None (Open Label)
Enrollment number
100
Postmarketing Clinical Study of Ipragliflozin - Long-term Study in Combination With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Post-Marketing Study to evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination with GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes Mellitus (T2DM)? Contact us by filling our your information to the right and we’ll respond to you.